Susan O’Brien

4.6k total citations
69 papers, 3.1k citations indexed

About

Susan O’Brien is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Susan O’Brien has authored 69 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Hematology, 34 papers in Genetics and 23 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Susan O’Brien's work include Chronic Lymphocytic Leukemia Research (29 papers), Acute Myeloid Leukemia Research (29 papers) and Chronic Myeloid Leukemia Treatments (26 papers). Susan O’Brien is often cited by papers focused on Chronic Lymphocytic Leukemia Research (29 papers), Acute Myeloid Leukemia Research (29 papers) and Chronic Myeloid Leukemia Treatments (26 papers). Susan O’Brien collaborates with scholars based in United States, Germany and United Kingdom. Susan O’Brien's co-authors include Hagop M. Kantarjian, Jörge E. Cortes, Farhad Ravandi, Guillermo Garcia‐Manero, Moshe Talpaz, Stefan Faderl, Elias Jabbour, Emil J. Freireich, Srđan Verstovšek and Francis J. Giles and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Susan O’Brien

67 papers receiving 3.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan O’Brien United States	29	2.2k	1.3k	949	686	575	69	3.1k
Mario Tiribelli Italy	25	1.3k 0.6×	922 0.7×	656 0.7×	277 0.4×	610 1.1×	97	2.2k
David Bowen United Kingdom	36	4.4k 2.0×	1.7k 1.4×	2.1k 2.2×	862 1.3×	500 0.9×	132	5.4k
José Cervera Spain	29	1.5k 0.7×	519 0.4×	1.4k 1.5×	487 0.7×	341 0.6×	129	2.6k
Steven Knapper United Kingdom	23	1.7k 0.8×	825 0.7×	1.2k 1.2×	323 0.5×	286 0.5×	91	2.4k
Aleksander B. Skotnicki Poland	20	856 0.4×	1.2k 0.9×	493 0.5×	308 0.4×	461 0.8×	130	2.3k
Luca Maurillo Italy	30	2.0k 0.9×	1.1k 0.9×	1.1k 1.2×	733 1.1×	499 0.9×	134	3.3k
Angelo Guerrasio Italy	24	938 0.4×	547 0.4×	787 0.8×	315 0.5×	255 0.4×	105	1.7k
Jan Samuelsson Sweden	26	1.9k 0.9×	1.9k 1.5×	1.2k 1.2×	113 0.2×	271 0.5×	75	2.8k
Robert Schoch Germany	12	1.7k 0.8×	604 0.5×	972 1.0×	352 0.5×	282 0.5×	21	2.3k
Agnieszka Wierzbowska Poland	22	1.5k 0.7×	461 0.4×	1.1k 1.2×	435 0.6×	483 0.8×	108	2.3k

Countries citing papers authored by Susan O’Brien

Since Specialization

Citations

This map shows the geographic impact of Susan O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan O’Brien more than expected).

Fields of papers citing papers by Susan O’Brien

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan O’Brien. The network helps show where Susan O’Brien may publish in the future.

Co-authorship network of co-authors of Susan O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Susan O’Brien. A scholar is included among the top collaborators of Susan O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan O’Brien. Susan O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gökbuget, Nicola, Anjali S. Advani, Matthias Stelljes, et al.. (2019). Impact of minimal residual disease status in patients with relapsed/refractory acute lymphoblastic leukemia treated with inotuzumab ozogamicin in the phase III INO-VATE trial. Leukemia Research. 88. 106283–106283. 37 indexed citations

Jabbour, Elias, Susan O’Brien, Farhad Ravandi, & Hagop M. Kantarjian. (2015). Monoclonal antibodies in acute lymphoblastic leukemia. Blood. 125(26). 4010–4016. 111 indexed citations

Montalban‐Bravo, Guillermo, Hagop M. Kantarjian, Jörge E. Cortes, et al.. (2015). Clinical Impact of First Complete Remission (CR1) Duration on Outcome of Patients with Relapsed Philadelphia Negative Pre-B Acute Lymphoblastic Leukemia (ALL). Blood. 126(23). 2504–2504. 1 indexed citations

Wodarz, Dominik, Naveen Garg, Natalia L. Komarova, et al.. (2014). Kinetics of CLL cells in tissues and blood during therapy with the BTK inhibitor ibrutinib. Blood. 123(26). 4132–4135. 78 indexed citations

Ravandi, Farhad, Gautam Borthakur, Guillermo Garcia‐Manero, et al.. (2014). Survivorship in APL- Outcomes of Acute Promyelocytic Leukemia (APL) Patients (pts) after Maintaining Complete Remission (CR) for at Least 3 Years. Blood. 124(21). 954–954. 6 indexed citations

Ghanem, Hady, A. Megan Cornelison, Guillermo Garcia‐Manero, et al.. (2013). Decitabine Can Be Safely Reduced After Achievement of Best Objective Response in Patients With Myelodysplastic Syndrome. Clinical Lymphoma Myeloma & Leukemia. 13. S289–S294. 2 indexed citations

Jabbour, Elias, Hagop M. Kantarjian, Farhad Ravandi, et al.. (2010). A phase 1‐2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndrome. Cancer. 117(6). 1236–1244. 32 indexed citations

Ravandi, Farhad, Jean‐Pierre J. Issa, Guillermo Garcia‐Manero, et al.. (2009). Superior outcome with hypomethylating therapy in patients with acute myeloid leukemia and high‐risk myelodysplastic syndrome and chromosome 5 and 7 abnormalities. Cancer. 115(24). 5746–5751. 68 indexed citations

Kantarjian, Hagop M., Susan O’Brien, Farhad Ravandi, et al.. (2008). Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 113(6). 1351–1361. 345 indexed citations

10.

Jabbour, Elias, Jörge E. Cortes, Francis J. Giles, Susan O’Brien, & Hagop M. Kantarjian. (2006). The clinical challenge of imatinib resistance in chronic myeloid leukemia: emerging strategies with new targeted agents. Targeted Oncology. 1(4). 186–196. 10 indexed citations

11.

Garcia‐Manero, Guillermo, Hagop M. Kantarjian, Blanca Sánchez‐González, et al.. (2005). Final Results of a Phase I/II Study of the Combination of the Hypomethylating Agent 5-aza-2′-Deoxycytidine (DAC) and the Histone Deacetylase Inhibitor Valproic Acid (VPA) in Patients with Leukemia.. Blood. 106(11). 408–408. 3 indexed citations

12.

Faderl, Stefan, Varsha Gandhi, Srđan Verstovšek, et al.. (2004). Clofarabine Plus Cytarabine (ARA-C) Combination Is Active in Newly Diagnosed Patients (PTS) ≥ Age 50 with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS).. Blood. 104(11). 875–875. 11 indexed citations

13.

Yazji, Salim, Francis J. Giles, Apostolia M. Tsimberidou, et al.. (2003). Antithymocyte globulin (ATG)-based therapy in patients with myelodysplastic syndromes. Leukemia. 17(11). 2101–2106. 65 indexed citations

14.

Kantarjian, Hagop M., Moshe Talpaz, Jörge E. Cortes, et al.. (2003). Quantitative polymerase chain reaction monitoring of BCR-ABL during therapy with imatinib mesylate (STI571; gleevec) in chronic-phase chronic myelogenous leukemia.. PubMed. 9(1). 160–6. 81 indexed citations

15.

O’Brien, Susan, et al.. (1996). Treatment of chronic myelogenous leukemia: current status and investigational options [see comments]. Blood. 87(8). 3069–3081. 155 indexed citations

16.

Hester, Jeane P., María Cecilia Dignani, Elias Anaissie, et al.. (1995). Collection and transfusion of granulocyte concentrates from donors primed with granulocyte stimulating factor and response of myelosuppressed patients with established infection. Journal of Clinical Apheresis. 10(4). 188–193. 67 indexed citations

17.

Kantarjian, Hagop M., Susan O’Brien, Terry Smith, et al.. (1994). Acute lymphocytic leukaemia in the elderly: characteristics and outsome with the vincristine‐adriamycin‐dexamethasone (VAD) regimen. British Journal of Haematology. 88(1). 94–100. 46 indexed citations

18.

Giralt, Sergio, Hagop M. Kantarjian, Albert Deisseroth, et al.. (1993). Preliminary Results of Treatment with Filgrastim for Relapse of Leukemia and Myelodysplasia after Allogeneic Bone Marrow Transplantation. New England Journal of Medicine. 329(11). 757–761. 77 indexed citations

19.

Talpaz, Moshe, Michael J. Keating, Elihu H. Estey, et al.. (1991). Intensive chemotherapy induction followed by interferon-alpha maintenance in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Cancer. 68(6). 1201–1207. 34 indexed citations

20.

Griffith, Reginald, E. J. Allen, Susan O’Brien, & P. J. O’Brien. (1984). Comparisons of growth and early yields of potato varieties of contrasting maturity classification at three sites. The Journal of Agricultural Science. 103(2). 443–458. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact